Interleukin 2 News and Research

RSS

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

Now, a new report describes a case of a coincidental mRNA vaccination and SARS-CoV-2 infection in a 31-year-old doctor, addressing the theoretical considerations for potential risks and further required actions in case more cases appear in the future.

11 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Are infants at greater risk of COVID-19 than children?

The widely circulating SARS-CoV-2 has caused the devastating COVID-19 pandemic. The impact of this infection varies significantly with age, sparing young children for the most part, though not completely. However, a new study, released as a preprint on the medRxiv* server, shows that infants are not as resistant to the virus as children are. The researchers trace this to the expression of ACE2 to varying extents in different groups.

7 May 2021

Transplant recipients with COVID-19 may show lower cellular and antibody immune responses

Transplant patients are typically on chronic immunosuppression, making them automatically more vulnerable to infection with SARS-CoV-2, the agent responsible for the loss of over three million lives in the current COVID-19 pandemic. A new study discusses evidence for subnormal immune responses following COVID-19 in this population.

6 May 2021

Aberrant immune features in healthy elderly and male subjects with severe COVID-19 may predate infection

A new study shows that the immunological features of severe COVID-19 are already present in healthy older adults and in men, before they are infected, indicating a possible explanation for this differential susceptibility towards the virus.

6 May 2021

Could stem cells improve the outcome of ARDS in severe COVID-19?

A recent study, published in Stem Cells Translational Medicine, explores the safety and efficacy of stem cells, which have been touted as the panacea for a wide range of illnesses, ranging from chronic degenerative conditions to cancer.

6 May 2021

Mental health may influence a person's recovery after heart attack

Young and middle-aged adults who reported severe psychological distress--such as depression or anxiety--after suffering a heart attack were more than twice as likely to suffer a second cardiac event within five years compared with those experiencing only mild distress, according to a study presented at the American College of Cardiology's 70th Annual Scientific Session.

6 May 2021

Monocytes promote viral control during SARS-COV-2 infection

In a paper recently uploaded to the preprint server bioRxiv by Vanderheiden et al. (May 4th, 2021) the contribution of monocytes in promoting protective immunity from SARS-CoV-2 is investigated in a murine model, suggesting that CCR2 plays the role of an inflammation modulator in early infection.

6 May 2021

Study uncovers protein 'signature' of severe COVID-19

Researchers at Massachusetts General Hospital have identified the protein "signature" of severe COVID-19, which they describe in a new study published in Cell Reports Medicine.

4 May 2021

What happens in the first few days of SARS-CoV-2 infection?

New research, published in PLOS Biology, has evaluated SARS-CoV-2 infection in primary cultures of well-differentiated cells to determine how the virus affects the body and how the infection starts. Answers to these questions are essential to forming a general understanding of viral pathogenesis, which helps us develop effective prevention and treatment strategies for COVID-19.

4 May 2021

"COVID-19 diarrhea" depends on inflammatory response that is part of the disease

Researchers in the United States have provided important insights into the pathophysiology of diarrhea that occurs in some cases of coronavirus disease 2019 (COVID-19).

29 Apr 2021

Host protein mimicry of SARS-CoV-2 receptor binding motif

In a new study, structural bioinformatics approaches are employed to investigate the potential mimicry of the receptor-binding motif (RBM) of these three coronaviruses, finding that several proteins from both human and non-human sources were similar to each, with implications regarding the mechanism of infection and tropism of SARS-CoV-2.

29 Apr 2021

SARS-CoV-2 clade linked to disease severity in the early phase of the pandemic

A new study in the journal JAMA Network reports on the disease severity associated with some clades of the virus, from an analysis of genomes from specimens isolated in the initial phase of the pandemic.

27 Apr 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

Interleukin 11-producing fibroblasts can be potential therapeutic targets for treating colorectal cancer

IL-11 is known to promote the development of colorectal cancer in humans and mice, but when and where IL-11 is expressed during cancer development is unknown.

22 Apr 2021

Research team identifies new factor in the development of psoriasis

Psoriasis is a common inflammatory skin condition. The underlying genetic factors have not yet been sufficiently researched.

19 Apr 2021

SARS-CoV-2 does not directly infect the brain but can inflict neurological damage

SARS-CoV-2, the virus that causes COVID-19, likely does not directly infect the brain but can still inflict significant neurological damage, according to a new study from neuropathologists, neurologists, and neuroradiologists at Columbia University Vagelos College of Physicians and Surgeons.

17 Apr 2021

Intestinal worm infection can cause severe sexually transmitted viral diseases

Infection with parasitic intestinal worms (helminths) can apparently cause sexually transmitted viral in-fections to be much more severe elsewhere in the body.

16 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

Interleukin 2 News and Research

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Are infants at greater risk of COVID-19 than children?

Transplant recipients with COVID-19 may show lower cellular and antibody immune responses

Aberrant immune features in healthy elderly and male subjects with severe COVID-19 may predate infection

Could stem cells improve the outcome of ARDS in severe COVID-19?

Mental health may influence a person's recovery after heart attack

Monocytes promote viral control during SARS-COV-2 infection

Study uncovers protein 'signature' of severe COVID-19

What happens in the first few days of SARS-CoV-2 infection?

"COVID-19 diarrhea" depends on inflammatory response that is part of the disease

Host protein mimicry of SARS-CoV-2 receptor binding motif

SARS-CoV-2 clade linked to disease severity in the early phase of the pandemic

Celastrol shows potential anti-SARS-CoV-2 activity

Interleukin 11-producing fibroblasts can be potential therapeutic targets for treating colorectal cancer

Research team identifies new factor in the development of psoriasis

SARS-CoV-2 does not directly infect the brain but can inflict neurological damage

Intestinal worm infection can cause severe sexually transmitted viral diseases

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News